Patients with established DKD, who were not given HCQS for the same duration of time in addition to their regular medication.
After that, we did a comparison between the mean end points of two groups (HCQS and Non-HCQS) at the end of 3 months by independent t test, where we compared end point LDL, HDL, TGs and total Cholesterol.
Role of HCQS in regression of Db Nephropathy in DKD patients can be explained by its action via several mechanism, one of which is making lipid profile favourable, (2, 6) which we tried to find out in our study.
While TG was reduced in both the groups, 24.69% and 10.66% in the HCQS and NON-HCQS group respectively, both of which were statistically significant (Table 4, Figure 3), the LDL-cholesterol was reduced by 10.24 % in HCQS group while it continued to increase by 14%, in the NON-HCQS group, after a follow up of 3 months.
Also, although total cholesterol declined in both the groups (Table 3, Figure 2), it was more in the HCQS group.
Also, the rise of HDL was only significant only in the HCQS group (Table 5, Figure 4)
The HCQS Group had significantly lower levels of LDL and TG and significant increase in the HDL levels while Cholesterol levels were not significantly changed between the two groups.
These favourable Lipid Profile changes in the HCQS Group not only prove that its combination with atorvastatin is a better treatment option for dyslipidemia in DKD patients but may also explain why this drug is so effective in retarding the progression of Diabetic Nephropathy in such patients.
Our study proved that HCQS in dosage of 100mg bd in combination with atorvastatin 20mg lowers LDL levels better than Atorvastatin 20 mg alone in DKD patients.
To conclude, HCQS while an anti-malarial, may have effects that include lowering bad cholesterol (LDL) and favouring good cholesterol (HDL) along with regression of Diabetic nephropathy in the Diabetic kidney disease patients, which may also explain the reason of its effectiveness in retarding progression of nephropathy in such patients and it may be combined with Atorvastatin for better lowering of lipid levels and better control of dyslipidemia in the DKD patients.